Humaid Al-Shamsi: Transforming Early Cancer Detection with Liquid Biopsy
Humaid Al-Shamsi, Visiting Professor at Harvard Medical School. shared on LinkedIn:
“Honoured to visit Datar Cancer Genetics UK at their HQ in Surrey Research Park, Guildford (UK) – a world-class molecular oncology facility advancing non-invasive liquid biopsy.
Grateful to Dr. Vineet Datta, Pankaj Porje and the outstanding scientific team for an in-depth tour of their end-to-end platform integrating ctDNA and circulating tumor cell (CTC) analytics.
Highlight: Their multi-cancer early-detection assays, built on combined CTC/ctDNA technology, are pushing liquid biopsy toward routine clinical practice and transforming the landscape of early detection and screening.
Notably, Datar’s innovation track includes FDA Breakthrough Device Designations for:
- TriNetra-Breast (early breast cancer detection)
- TriNetra-Prostate (early prostate cancer detection)
- TriNetra-Glio (blood test to aid diagnosis of otherwise inaccessible brain tumors)
Thank you to Rajan Datar, Founder of Datar Cancer Genetics, and Dr. Vineet Datta for the kind invitation. Your work is simply impressive.
Looking forward to collaborating to help our communities detect cancer earlier and improve cure rates.”
More posts featuring Humaid Al-Shamsi.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023